Raloxifene (20mg/capsule), 60 Capsules
Original price was: $99.95.$85.95Current price is: $85.95.
Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits tissue-specific agonist and antagonist activity at estrogen receptors (ERs). It interacts with ERα and ERβ, influencing gene transcription and receptor-mediated signaling CAS: 84449-90-1 | Formula: C28H27NO4S | Content: 5 grams | Research use only | Third-party lab tested.
Buy Raloxifene (20mg/capsule), 60 Capsules – Swiss Chems USA
Raloxifene (20mg/capsule), 60 Capsules — Research Overview
Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits tissue-specific agonist and antagonist activity at estrogen receptors (ERs). It interacts with ERα and ERβ, influencing gene transcription and receptor-mediated signaling pathways.
This compound undergoes hepatic metabolism primarily via glucuronidation, producing inactive glucuronide conjugates.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
Intended use: This material is supplied for laboratory and in-vitro research only. It is not a drug, food, or cosmetic and is not intended for human or animal consumption.
Raloxifene (20mg/capsule), 60 Capsules Chemical Properties
| Property | Specification |
|---|---|
| Chemical Formula | C28H27NO4S |
| Synonyms | Keoxifene, LY156758 |
| Molar Mass | 473.58 g/mol |
| CAS Number | 84449-90-1 |
| PubChem CID | 5035 |
| Total Compound Content | 5 grams |
| Shelf Life | 36 months |
Raloxifene (20mg/capsule), 60 Capsules Research Applications
Raloxifene binds competitively to both estrogen receptor subtypes (ERα and ERβ), producing conformational changes in the receptor that recruit different coactivator/corepressor complexes depending on the target tissue — the structural basis of its tissue-selective agonist/antagonist profile. In bone tissue, this conformation favors estrogen-agonist-like signaling, supporting research into its effects on bone mineral density and osteoclast activity. In breast and uterine tissue, the resulting conformation instead favors antagonist activity, a key research contrast point against tamoxifen, which retains partial agonist activity in the endometrium. Research models frequently compare raloxifene against tamoxifen and other SERMs to characterize how ligand structure determines coactivator recruitment and downstream tissue selectivity. Unlike tamoxifen, raloxifene does not require CYP2D6-mediated metabolism to an active form, making it a useful comparative tool in studies of SERM pharmacokinetics and metabolic activation pathways. Independently third-party HPLC-tested; COA available per batch.
Raloxifene (20mg/capsule), 60 Capsules Frequently Asked Questions
What makes raloxifene’s tissue selectivity distinct from tamoxifen’s in receptor pharmacology research?
Both compounds bind the estrogen receptor, but the resulting receptor conformation differs in ways that alter coactivator/corepressor recruitment by tissue. Raloxifene’s conformation favors antagonist activity in both breast and endometrial tissue, whereas tamoxifen retains partial agonist activity in the endometrium. This divergence makes head-to-head SERM studies a common approach for mapping how structural differences in ligands translate into tissue-specific transcriptional outcomes.
How is raloxifene used in bone metabolism research models?
Because raloxifene’s receptor conformation in bone tissue favors estrogen-agonist-like signaling, it is used in osteoblast/osteoclast culture models and in vivo bone density studies to examine estrogen-receptor-mediated effects on bone turnover, independent of the antagonist activity it shows in reproductive tissue.
What distinguishes raloxifene’s metabolic pathway from other SERMs in pharmacokinetic research?
Raloxifene undergoes extensive glucuronidation rather than requiring CYP2D6-mediated bioactivation, unlike tamoxifen, which depends on CYP2D6 conversion to its active metabolite endoxifen. This makes raloxifene a useful comparator in research examining how metabolic activation requirements affect SERM activity and inter-individual variability tied to CYP2D6 polymorphisms.
Research Use Disclaimer
All product information is provided for educational and laboratory research reference only. Any form of introduction into humans or animals is prohibited. Handle only in licensed research settings in accordance with applicable laws and institutional protocols.
| Weight | 3 lbs |
|---|
Reviews
There are no reviews yet.